Skip to main content
Fig. 4 | Cancer Nanotechnology

Fig. 4

From: HepG2 exosomes coated luteolin nanoparticles remodeling hepatic stellate cells and combination with sorafenib for the treatment of hepatocellular carcinoma

Fig. 4

In vitro cytotoxicity of luteolin and sorafenib at different concentrations to HepG2 cells and LX2 cells. A Cell viability of LX2 cells treated with luteolin with increasing dosage for 24 h. B Cell viability of LX2 cells treated with sorafenib for 24 h. C Cell viability of HepG2 cells treated with sorafenib for 48 h measured by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay. IC50 and IC80 were determined by dose–response curves using GraphPad Prism software (Version 8.0.1). Data are represented as mean ± SD (n = 5)

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us